β- and γ-diketones and γ-hydroxyketones as
The present invention discloses β-diketones, γ-diketones or γ-hydroxyketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries related to the differentiation and development of the central nervous system, comprising Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, comprising hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
1. A compound or pharmaceutically acceptable salt thereof having the structure of Formula I:
wherein R 1 is a substituted or unsubstituted heteroaryl, wherein the heteroaryl is selected from the group consisting of
with the proviso that a carbon atom of the R 1 heteroaryl is attached to the carbonyl;
R 2 is a substituted or unsubstituted aryl, wherein the aryl is selected from phenyl or naphthyl; and
R 3 , R 4 , R 5 and R 6 are H.
2. The compound of claim 1 having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , wherein R 1 is
and R 2 a substituted or unsubstituted phenyl.
4. The compound of claim 3 , wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 3 , wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 3 , wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 1 , wherein R 1 is
8. The compound of claim 1 , wherein R 2 is a substituted or unsubstituted phenyl.
9. A pharmaceutical composition comprising a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof having the structure of Formula I:
wherein R 1 is a substituted or unsubstituted heteroaryl, wherein the heteroaryl is selected from the group consisting of
with the proviso that a carbon atom of the R 1 heteroaryl is attached to the carbonyl;
R 2 is a substituted or unsubstituted aryl, wherein the aryl is selected from phenyl or naphthyl; and
R 3 , R 4 , R 5 and R 6 are H;
and a pharmaceutically acceptable excipient.
10. A pharmaceutical composition of claim 9 , wherein R 1 is
11. A pharmaceutical composition of claim 9 , wherein R 2 is a substituted or unsubstituted phenyl.
12. A pharmaceutical composition of claim 9 , wherein R 1 is
and R 2 is a substituted or unsubstituted phenyl.
13. A pharmaceutical composition of claim 9 having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
14. A pharmaceutical composition of claim 9 , wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition of claim 9 , wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition of claim 9 , wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.